Please assess the completion status of the following clinical trial:

Trial Title: Use of Transdermal Clonidine in Trauma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ventilated male or female trauma patient 18 years of age or older admitted to the ICU \>24 hours~2. Patient must meet minimal medical criteria for potential extubation (meet criteria for being placed on spontaneous breathing trials per established MUMC SBT protocol)~3. Patients must exhibit delirium as assessed by the CAM-ICU assessment tool~4. Patient must be declared stable from a neurologic, respiratory and cardiovascular standpoint to receive clonidine by the attending MD~5. Consent must be obtained prior to any study procedures~Exclusion Criteria:~1. Patient \< 18 years old~2. Bradycardia (HR \< 60)~3. Presence of active pacemaker~4. Hypotensive (\<90/60)or active treatment of hypotension with vasoactive medications~5. Patient actively being treated with Clonidine or dexmedetomidine~6. Presence of allergy to Clonidine~7. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transdermal Clonidine/Oral Clonidine (Type: EXPERIMENTAL): An oral loading dose of Clonidine 0.3 mg and placement of a Clonidine Transdermal system at a dose of 0.3 mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3 mg after 12 hours
- Comparator (Type: PLACEBO_COMPARATOR): Placebo group will receive a placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).